title: Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
authors.affiliation: IDEC Pharmaceuticals Corporation, San Diego, CA 92121, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Anderson
authors.forename: A
authors.initials: A
authors.lastname: Grillo-López
authors.forename: C
authors.initials: C
authors.lastname: Varns
authors.forename: K S
authors.initials: KS
authors.lastname: Chambers
authors.forename: N
authors.initials: N
authors.lastname: Hanna
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000920:Antibody-Dependent Cell Cytotoxicity; D015703:Antigens, CD / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D017322:Clinical Trials, Phase II as Topic; D003167:Complement Activation; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D018951:Antigens, CD20; D000069283:Rituximab